Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 33 Show results per page	View Search Criteria \| Help With Results

Last Modified: 6/12/2008 First Published: 5/28/2004


1.		Phase III Study of Radiotherapy, High-Dose Cisplatin, Vincristine, and Cyclophosphamide, and Autologous Stem Cell Rescue in Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				3 to 21 at diagnosis				NCI				SJCRH-SJMB03 NCT00085202

Last Modified: 10/17/2008 First Published: 6/2/2006


2.		Phase III Randomized Study of Induction Chemotherapy Comprising Vincristine, Etoposide, Cyclophosphamide, and Cisplatin With or Without High-Dose Methotrexate and Leucovorin Calcium Followed by Consolidation Chemotherapy Comprising Carboplatin and Thiotepa and Peripheral Blood Stem Cell Rescue in Pediatric Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				Under 3				NCI				COG-ACNS0334 ACNS0334, NCT00336024

Last Modified: 6/11/2008 First Published: 10/21/2006


3.		Phase III Pilot Study of Induction Chemotherapy Followed by Consolidation Myeloablative Chemotherapy Comprising Thiotepa and Carboplatin With or Without Etoposide and Autologous Hematopoietic Stem Cell Rescue in Pediatric Patients With Previously Untreated Malignant Brain Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 10 at diagnosis				Other				CHLA-HEAD-START-III CHLA-HSIII, CHLA-2004-020, CHLA-04.020, NCT00392886, UMN-MT2004-06

Last Modified: 10/17/2008 First Published: 10/21/2006


4.		Phase III Randomized Study of Standard Chemoradiotherapy With or Without Carboplatin Followed by Standard Maintenance Therapy With or Without Isotretinoin and Continuation Therapy With Isotretinoin Versus No Continuation Therapy in Pediatric Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				3 to 21				NCI				COG-ACNS0332 ACNS0332, NCT00392327


5.		A Phase I/II Study of the Photon Radiosurgery System

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				2 to 32				Other				CNS 0201 NCT00179907


6.		Intracerebral Clysis in Treating Patients With Recurrent Primary Brain Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				1 to 120				Other				R01 CA 89395-01 Topotecan, Brain Tumors, Intracerebral Clysis, NCT00452959


7.		A Multi-Center Phase I Study of AP23573 in Pediatric Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				1 to 17				Other				SUN08-01 NCT00704054

Last Modified: 11/2/2007 First Published: 11/1/1998


8.		Phase II Study of Antineoplastons A10 and AS2-1 in Children With Brain Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				6 months to 17 years				Other				BC-BT-10 NCT00003458

Last Modified: 11/2/2007 First Published: 11/1/1998


9.		Phase II Study of Antineoplastons A10 and AS2-1 in Children With Primitive Neuroectodermal Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				6 months to 17 years				Other				BC-BT-12 NCT00003460

Last Modified: 12/21/2007 First Published: 10/25/2004


10.		Phase II Study of Lapatinib in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Primitive Neuroectodermal Tumors, High-Grade Glioma, or Ependymoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				21 and under				NCI				PBTC-016 PBTC-016, NCT00095940

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute